Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, alendronic acid (Steovess®) once-weekly 70 mg effervescent tablets cannot be endorsed for use within NHS Wales for the treatment of postmenopausal osteoporosis. |
||
|
||
Medicine details |
||
| Medicine name | alendronic acid (Steovess®) | |
| Formulation | 70 mg effervescent tablet | |
| Reference number | 1612 | |
| Indication | Treatment of postmenopausal osteoporosis. |
|
| Company | Nycomed UK Ltd | |
| BNF chapter | Endocrine system | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 07/08/2012 | |